Search clinical trials for: Recombinant Interleukin-2

Total 18655 results

Icahn School of Medicine at Mount Sinai

Completed

Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency

Common Variable Immunodeficiency
Aalborg University Hospital

Unknown

Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2 (HEPVACHIV)

HIV Infections | Hepatitis B | Hepatitis A

Denmark
National Cancer Institute (NCI)

Terminated

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Leukemia | Chronic | Lymphocytic | B-Cell

United States
Washington University School of Medicine
National Cancer Institute (NCI); American Society of Clinical Oncology; ImmunityBio... and other collaborators

Terminated

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Leukemia, Myeloid, Acute

United States
Astellas Pharma Global Development, Inc.

Completed

Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer (PILOT)

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction | CLDN18.2-positive Adenocarcinoma of Esophagus | CLDN18.2-positive Gastric Adenocarcinoma

Germany, Latvia
King's College London
King's College Hospital NHS Trust

Terminated

Low-dose IL-2 for Treg Expansion and Tolerance (LITE) (LITE)

Liver Diseases | Transplantation

United Kingdom
National Cancer Institute (NCI)

Terminated

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

Clear-Cell Renal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

Mycosis Fungoides | Sezary Syndrome | Anaplastic Large Cell Lymphoma | Peripheral T-cell Lymphoma NOS

United States
Vical
National Cancer Institute (NCI); Jonsson Comprehensive Cancer Center

Terminated

Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Lava Therapeutics

Active, not recruiting

Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Lymphocytic Leukemia

United States, Spain, France, Netherlands
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Interleukin-12 in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Rockefeller University

Completed

Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2

HIV Infections

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)
The Cleveland Clinic

Completed

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma

Kidney Cancer | Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Radboud University Medical Center

Unknown

The Effect of Anakinra on Insulin Secretion

Glucose Intolerance | Diabetes Mellitus Type 2 | Impaired Insulin Secretion

Netherlands
Masonic Cancer Center, University of Minnesota

Withdrawn

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Pulmonary Metastases | Metastatic Melanoma | Brain Metastases | Hepatic Metastases

United States
Vical
National Cancer Institute (NCI); Jonsson Comprehensive Cancer Center

Terminated

Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer

Prostate Cancer

United States
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC

Completed

The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial (ACTIVATE)

Advanced Ovarian Cancer | Malignant Melanoma

Canada
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail

Locally Advanced Rectal Adenocarcinoma

China
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases (TRANSREG)

Rheumatoid Arthritis | Systemic Lupus Erythematosus | Psoriasis | Systemic Sclerosis | Crohn's Disease | Ulcerative Colitis | Idiopathic Thrombocytopenic Purpura | Autoimmune Hepatitis | Wegener's Granulomatosis | Ankylosing Spondylitis | Behcet's Disease | Takayasu's Disease | Sclerosing Cholangitis | Gougerot-sj...

France
Cambridge University Hospitals NHS Foundation Trust

Not yet recruiting

The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution. (ELLIPSE)

Carotid Artery Plaque | Carotid Atherosclerosis | TIA

United Kingdom
National Cancer Institute (NCI)

Completed

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
Shanghai Gebaide Biotechnology Co., Ltd.

Unknown

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

Non-small-cell Lung Cancer (NSCLC) Stage IV

China
The First Affiliated Hospital of Guangzhou Medical...

Withdrawn

Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19

COVID-19

China
Bayer

Completed

Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection

HIV Infections

France, United States, United Kingdom
Beijing Northland Biotech. Co., Ltd.

Completed

A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11

Chemotherapy-induced Thrombocytopenia

China
Roswell Park Cancer Institute

Active, not recruiting

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Refractory Ovarian... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Recurrent Non-Small Cell Lung Carcinoma | Recurrent Pleural Malignant Mesothelioma | Stage III Pleural Malignant Mesothelioma AJCC v7 | Stage IV Pleural Malignant Mesothelioma AJCC v7 | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | HLA-A*0201 Positive... and other conditions

United States
Abramson Cancer Center of the University of Pennsylvania

Withdrawn

A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian, Fallopian Tube and Peritoneal Cancer

United States
Ahmad Tarhini
Prometheus Laboratories

Terminated

A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study

Melanoma

United States
University of Washington
National Cancer Institute (NCI)

Completed

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer

Cancer

United States
Beijing Tongren Hospital

Completed

A Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis (MERAK)

Allergic Rhinitis

China
Beth Israel Deaconess Medical Center
National Cancer Institute (NCI)

Unknown

Interleukin-12 in Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy and Peripheral Stem Cell Transplantation

Breast Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Northwestern University

Completed

Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer

Lymphoma | Leukemia | Breast Cancer | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
Gregory Daniels
Immunotherapy Foundation

Recruiting

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Metastatic Melanoma | Metastatic Head and Neck Cancer | Locally Advanced Refractory/Recurrent Melanoma | Locally Advanced Refractory/Recurrent Head and Neck Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in Remission | Recurrent... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation

Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia and other conditions

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic
University Health Network, Toronto

Completed

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

Metastatic, Stage III or Stage IV, Melanoma

Canada
St. Louis University
Major Extremity Trauma Research Consortium

Terminated

rhBMP-2 Versus Autograft in Critical Size Tibial Defects

Tibial Fractures

United States
M.D. Anderson Cancer Center

Completed

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Recurrent Synovial Sarcoma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present | Recurrent Myxoid Liposarcoma

United States
University of Alabama at Birmingham

Completed

Early Treatment of Cytokine Storm Syndrome in Covid-19

COVID-19 | Cytokine Storm

United States

Search clinical trials for: Recombinant Interleukin-2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations